Abstract: A pharmaceutical formulation of a pharmaceutically active protein including an effective amount of a protein or a combination of proteins, a chitosan A and at least one statistic polysaccharide B. Also, a kit including the at least one first container containing the chitosan A and the statistic polysaccharide B and at least one second container containing the protein or combination of proteins. Further, the pharmaceutical formulation or the kit for use in the treatment of cancer, typically breast or gastric cancer.

Abstract: A computer-implemented method for managing/monitoring production of agricultural raw materials useful for the production of alcoholic beverages, as well as the production, storage, ageing, consumption, quality, authenticity, traceability and/or selling price of alcoholic beverages comprises: (a) collecting two samples of the alcoholic beverage in an inert container sealed with an inert stopper; (b) assigning data on the alcoholic beverage to each sample; (c) storing at least some of the samples collected in step (a), under specified conditions; (d) analysing each sample to determine at least one mineral profile, preferably metallic; (e) forming a database relating to the samples and resulting from step (b) and step (d); (h) processing these data by statistical analysis, preferably using AI; and (i) using the processed data to manage/monitor the entire supply chain of the alcoholic beverage until its consumption. A device for implementing steps (a) and (c) of the method is also provided.

Abstract: The present invention relates to the field of compositions comprising a polymer bearing a chelating group capable of chelating one or more metals, and to the various uses thereof. In particular, the present invention relates to compositions comprising a copolysaccharide carrying a chelating group, which compositions may be in the form of a gel, as well as to the threads obtained from this gel.

Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

Abstract: A sleeve made of rigid tube into which the feed lines for feeding the waste to treated and the gases to be discharged lead. In order to avoid contamination or blockage of the sleeve, a tool for scraping the inner face of the wall thereof is added, in this case a terminal tubular section of one of the feed lines, which carries out orbital movements tangent to this inner face. Various cooling, rinsing and overpressure structures are added, as is a docking device extending at the bottom of the sleeve for connecting the latter to the heat treatment container.

Abstract: A method for obtaining a population of T cells from pluripotent stem cells, which includes a first step of obtaining hematopoietic stem cells and a second step of obtaining T cells. Also, the cell populations thus obtained according to this method and these cell populations for use as a medicament.

Abstract: The invention relates to a statistical polysaccharide with a weight-average molecular weight of between 100 kDa and 1000 kDa of the following formula (I): in which: each Rc independently represents a group containing a chelating agent, each Z independently represents a binder which may be a single bond or a hydrocarbon chain containing between 1 and 12 carbon atoms, said chain able to be either linear or branched and being able to contain one or more unsaturations and being able to contain one or more heteroatoms, preferably chosen from nitrogen, oxygen, sulfur and atoms of the halogen family, x is between 0.005 and 0.7, preferably between 0.05 and 0.7, and preferentially between 0.2 and 0.6, y is between 0.01 and 0.7, preferably between 0.05 and 0.2, the ratio of y/x being greater than or equal to 0.05, preferably greater than or equal to 0.15, and the sum of x+y being greater than or equal to 0.30, preferably greater than or equal to 0.35.

Abstract: The present invention provides a method for reprogramming a human somatic cell to a cell exhibiting at least one characteristic of a trophoblast stem cell (TSC), the method comprising the following steps in order: a) increasing the protein expression of one or more factors in the somatic cell, wherein the factors are for reprogramming the somatic cell towards a pluripotent state; b) culturing the cell for a sufficient time and under conditions to allow the reprogramming of the cell towards a pluripotent state; c) contacting the cell with a culture medium suitable for sustaining trophoblast stem cells (TSC); and d) culturing the cell in the TSC medium for a sufficient time and under conditions to allow the cell to exhibit at least one characteristic of a TSC, thereby reprogramming the somatic cell to a cell exhibiting at least one characteristic of a TSC.

Abstract: The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.

Abstract: The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.

Abstract: The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.

Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PH F) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

Abstract: The invention relates to a handheld aesthesiometer, comprising a gas lung connected with intermediation from first valve means to a source of gas and comprising an expandable cavity intended to house a volume of gas in a loading phase of the aesthesiometer; an outlet nozzle connected to the gas lung with intermediation from second valve means and suitable for directing a puff of the volume of the gas housed in the gas lung in a firing phase of the aesthesiometer; and a mechanism to ensure in the aforementioned firing phase of the aesthesiometer the release of the puff of the volume of gas contained in the gas lung in the direction of the outlet nozzle by means of a controlled contraction of the expandable cavity of the gas lung in order to ensure a substantially constant outlet pressure.

Abstract: The present invention relates to a film of chitosan and its use for the adhesion of microorganisms, preferably bacteria, a device for microorganism growth comprising a substrate and a film of chitosan deposited thereon, and a method for preparing said device. The device of the invention is more particularly useful in in vitro methods for observing and/or detecting microorganisms and/or biological processes involving microorganisms, said microorganisms being preferably bacteria. It can be used more specifically for in vitro determining the resistance or susceptibility of microorganisms to bioactive agents, said microorganisms being preferably bacteria.

Abstract: The present invention relates to an aqueous or hydro-alcoholic suspension of chitosan, dispersed cellulose nanofibers, and an acid, which is suitable for obtaining a hydrogel composite comprising a network of chitosan and cellulose nanofibers. The suspension of the invention is useful for tissue regeneration and the hydrogel of the invention is useful as bioresorbable and biocompatible implant.

Abstract: The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.

Abstract: The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.

Abstract: A method for obtaining a population of T cells from pluripotent stem cells, which includes a first step of obtaining hematopoietic stem cells and a second step of obtaining T cells. Also, the cell populations thus obtained according to this method and these cell populations for use as a medicament.

Abstract: The present invention relates to a homogeneous aqueous solution of injectable chitosan containing a chitosan having a degree of acetylation lower than 20%, said solution containing between 0.1 and 3.5% by weight of chitosan, said solution presenting a pH lower than 6.2, and said aqueous solution being capable of forming crystalline particles of chitosan after injection. The present invention also relates to compounds containing such a homogeneous aqueous solution of chitosan. The invention also relates to such compounds for their use as dermatological or cosmetic compounds, or for their use as a medical device, advantageously as a bioresorbable implant.